Posts by Sandra Ansanay-Alex
EIT Health’s Innovation Call
Apply before 13 January 2027 for the EIT Health’s Innovation Validation Call 2027. EIT supports innovative digital and AI–powered medical technologies that are ready for real-world clinical validation and are approaching market launch. This call addresses the funding gap for solutions that need to run clinical studies and collect evidence to demonstrate safety and efficacy,…
Read MoreEureka Globalstars x Japan
Swiss companies and research institutes are invited to undertake R&D projects partnering with Japanese start-up and SMEs. Apply before 20 January 2027. This call is open for all R&D projects, excluding technologies associated with nuclear power, pharmaceutical development, and regenerative medicine product development. Examples of scope include, but are not limited to quantum technology, artificial…
Read MoreFONGIT Life – Boosting LS Innovation with AI
This FONGIT Life Event, exploring how AI can boost Life Sciences Innovation, is taking place on 17 November 2026 at Campus Biotech Geneva. AI is accelerating innovation across the entire life sciences pipeline, from research collaborations and scientific discovery to clinical implementation and new healthcare solutions. This session, organised by FONGIT and the Swiss Data…
Read MoreFIF Supports Promising Life Sciences Projects
dEEGtal, S-SENTIA and Juturna Bio are the latest projects to receive funding from the FIF, the Canton of Geneva’s innovation financing programme supporting technology-driven startups, scale-ups and SMEs. dEEGtal has been awarded CHF 100’000 in FIF Seed Tech funding for its EEG analysis software. S-SENTIA has received the same amount for its 3D imaging microchip.…
Read MoreAlcon acquires Neurotech and the only approved treatment for MacTel type 2
Geneva-based eye care leader Alcon has acquired Neurotech Pharmaceuticals, a private biotech company developing therapies for chronic eye diseases, for USD 550 million, plus potential contingent payments linked to commercial milestones. Announced on 20 October 2026, the deal brings ENCELTO into Alcon’s portfolio: the only FDA-approved treatment for macular telangiectasia type 2 (MacTel). Alcon expects…
Read MoreOrbis Medicines Enters Multi-Target Drug Discovery Partnership with Novo Nordisk Worth up to USD 1.4 Billion
Orbis Medicines Signs Drug Discovery Deal with Novo Nordisk Worth Up to USD 1.4 billion Orbis Medicines, a biotech company based in Copenhagen and Lausanne, has entered a multi-target drug discovery and licensing partnership with Novo Nordisk. Announced on 17 September 2026, the agreement aims to develop oral medicines for cardiometabolic diseases that are currently…
Read MoreThree Swiss Health Valley Projects Supported by the EPFL Startup Launchpad
MazeBio, Akteon and HelixScreen are supported by the EPFL Startup Launchpad and taking the next steps towards bringing their technologies to market. MazeBio and Akteon have each received a CHF 30,000 Ignition Grant, while HelixScreen has been awarded a CHF 100,000 Innogrant. Spanning AI-powered drug discovery, compact flow cytometry, fusion energy and personalised cancer treatment, the…
Read MoreMillicent Dockerill Wins L’Oréal-UNESCO Award
Dr Millicent Dockerill, researcher at the University of Geneva’s Department of Organic Chemistry and founder of the UNIGE spin-off Reverso Therapeutics, is one of the four laureates of the 2026 Swiss L’Oréal–UNESCO For Women in Science Awards. The prize, worth CHF 25,000, will be presented on 21 October 2026 in Zurich. The awards are given…
Read MoreHUG Innovation Day: four projects awarded
On 15 October 2026, the Geneva University Hospitals (HUG) held the 20th edition of their Innovation Day. The event connects hospital, academic and economic players to help ideas from the field reach patients, and in some cases become patents or industrial products. From the bedside to the market, four projects were awarded. Thirteen projects were…
Read MoreReady to Sell? Deep Dive at Biopôle
Ready to sell? What it really takes to go from innovation to commercialisation.Your product is approved. Now what? On 5 October 2026, BioAlps and Biopôle brought about 40 founders, investors and ecosystem partners together at Biopôle in Lausanne for a Deep Dive on one of the hardest steps in a life sciences company’s journey: the…
Read More